OptimizeRx Corp.
OPRX Healthcare Health Information Services
OptimizeRx Corp.’s revenue for fiscal 2025 (year ended December 2025) was $109.4 million, up 18.8% from fiscal 2024. In the quarter to June 2026, revenue fell 29.8%, EPS fell 150.0%, free cash flow grew 89.9% and total debt fell 33.1%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow OPRX
OptimizeRx Corp. (OPRX) Piotroski F-score
OptimizeRx Corp.'s Piotroski F-score for fiscal 2025 is 8 out of 9: 8 of nine tests of profitability, leverage and efficiency passed, up from 5 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 8 | 3.00 |
| FY2024 | 5 | 3.00 |
| FY2023 | 2 | (2.00) |
| FY2022 | 4 | (3.00) |
| FY2021 | 7 | 4.00 |
| FY2020 | 3 | 0.00 |
| FY2019 | 3 | (5.00) |
| FY2018 | 8 | 4.00 |
| FY2017 | 4 | 1.00 |
| FY2016 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 2.95% | (11.34%) | Pass | 1 |
| Positive operating cash flow | 18.72m | 4.89m | Pass | 1 |
| Rising return on assets | 2.95% | (11.34%) | Pass | 1 |
| Cash flow above net income | 13.58m | 25.00m | Pass | 1 |
| Falling long-term leverage | 0.12 | 0.17 | Pass | 1 |
| Rising current ratio | 3.04 | 2.89 | Pass | 1 |
| No new shares issued | 18,555,000 | 18,293,000 | Fail | 0 |
| Rising gross margin | 67.25% | 64.45% | Pass | 1 |
| Rising asset turnover | 0.63 | 0.52 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 8 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| OPRX OptimizeRx Corp. | 8 |
| AMWL American Well Corporation compare | 6 |
| LFMD LifeMD, Inc. compare | 6 |
| CCLD CareCloud, Inc. compare | 6 |
| SPOK Spok Holdings, Inc. compare | 6 |
| HCAT Health Catalyst, Inc. compare | 5 |
| CSLT Castlight Health, inc. compare | 5 |
| DH Definitive Healthcare Corp. compare | 5 |
| SY So-Young International Inc. Sponsored ADR compare | 5 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover